Hesperidine Methylchalcone API Market

Hesperidine methylchalcone API market is projected to grow at a CAGR of 5.8% between 2025 and 2035, primarily due to its use in respiratory conditions. The market growth is driven by increasing demand for vascular health treatments, dietary supplements, and natural antioxidant-based cosmetics. Furthermore the market is supported by rising awareness of chronic venous disorders and a growing shift toward plant-based pharmaceutical ingredients.

Pharmaceutical applications dominate the market segment, accounting for the largest share due to the compound’s extensive use in treating chronic venous insufficiency (CVI), hemorrhoids, and capillary fragility. Hesperidin methylchalcone is often formulated with flavonoids like diosmin to enhance vascular protection and reduce inflammation. The nutraceutical segment is also expanding, fueled by the increasing popularity of natural supplements that support blood circulation, cardiovascular health, and skin integrity.

Geographically, Europe leads the global market, with France, Germany, and Italy serving as key hubs due to their well-established pharmaceutical sectors and high prevalence of venous diseases. North America, particularly the US, is experiencing growing demand through dietary supplements and over-the-counter CVI treatments. Meanwhile, Asia-Pacific especially India and China is emerging as a major manufacturing and export region for the API, owing to cost-effective production capabilities and expanding contract development and manufacturing services.

Prominent players in the global Hesperidin Methylchalcone API market include Shaanxi NHK Technology Co., Ltd, Xi’an Rainbow Biotech Co., Ltd, Ningbo Gianon Biotech Co., Ltd, and Hunan MT Health Inc. These companies are actively engaged in the production and distribution of high-purity plant extracts to meet growing global demand. Strategic collaborations, capacity expansion, and product standardization remain key growth strategies among leading manufacturers.